VanEck Associates’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$782K Buy
+5,551
New +$791K ﹤0.01% 1165

Other funds holding PTGX

VanEck Associates's PTGX Position: Q3 2026 in Review

VanEck Associates opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 5,551 shares worth $782K. The stake represents ﹤0.01% of the portfolio and ranks #1165 among its holdings.

379 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • VanEck Associates held 5,551 shares of Protagonist Therapeutics worth $782K as of Q3 2026.
  • Protagonist Therapeutics was a new VanEck Associates position in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q3 2026, its #1165 holding.
  • 379 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on VanEck Associates's 13F filing for Q3 2026, filed 13 Nov 2026.